AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36281496 — intervention group
Group type: EXPERIMENTAL
Intervention: ORMD‐0801 8 mg QD
Number of subjects: 373
Study 36281496 — intervention group
Group type: EXPERIMENTAL
Intervention: ORMD‐0801 32 mg QD
Number of subjects: 373
Study 36281496 — intervention group
Group type: EXPERIMENTAL
Intervention: ORMD‐0801 32 mg BID
Number of subjects: 373
Study 36281496 — intervention group
Group type: EXPERIMENTAL
Intervention: ORMD‐0801 16 mg QD
Number of subjects: 373
Study 36281496 — intervention group
Group type: EXPERIMENTAL
Intervention: ORMD‐0801 16 mg BID
Number of subjects: 373
Study 36281496 — intervention group
Group type: EXPERIMENTAL
Intervention: ORMD‐0801 32 mg TID
Number of subjects: 373
Study 36281496 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 373
Study 36243884 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal smoking during pregnancy (MSDP)
Number of subjects: 572
Study 36243884 — intervention group
Group type: COMPARATOR
Intervention: No maternal smoking during pregnancy (Control)
Number of subjects: 572
Study 34711436 — intervention group
Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted, cell culture-derived A/H5N1 influenza vaccine (aH5N1c), 7.5 µg hemagglutinin antigen per dose
Number of subjects: 0
Study 34711436 — intervention group
Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted, cell culture-derived A/H5N1 influenza vaccine (aH5N1c)
Number of subjects: 0
Study 34635114 — intervention group
Group type: EXPERIMENTAL
Intervention: Carglumic acid with standard treatment
Number of subjects: 38
Study 34635114 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment alone
Number of subjects: 38
Study 33105245 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 16 mg
Number of subjects: 146
Study 33105245 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 146
Study 35922611 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) group - 3-month physical training starting 6 weeks after BS
Number of subjects: 20
Study 35922611 — intervention group
Group type: COMPARATOR
Intervention: Control group - no specific activity
Number of subjects: 20
Study 32217274 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibular reposition taping (FRT)
Number of subjects: 60
Study 32217274 — intervention group
Group type: COMPARATOR
Intervention: Sham taping
Number of subjects: 60
Study 32217274 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 60
Study 36168738 — intervention group
Group type: EXPERIMENTAL
Intervention: NeuFlex implant
Number of subjects: 72
Study 36168738 — intervention group
Group type: COMPARATOR
Intervention: Integra implant
Number of subjects: 72
Study 33809720 — intervention group
Group type: EXPERIMENTAL
Intervention: Bell pepper extract enriched for rhamnogalacturonan-I (bpRG-I)
Number of subjects: 0
Study 33809720 — intervention group
Group type: EXPERIMENTAL
Intervention: Carrot extract enriched for rhamnogalacturonan-I (cRG-I)
Number of subjects: 0
Study 33373691 — intervention group
Group type: EXPERIMENTAL
Intervention: High calorie shake
Number of subjects: 99
Study 33373691 — intervention group
Group type: COMPARATOR
Intervention: Low calorie shake
Number of subjects: 99
Study 33429977 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 g xylitol
Number of subjects: 12
Study 33429977 — intervention group
Group type: EXPERIMENTAL
Intervention: 17 g xylitol
Number of subjects: 12
Study 33429977 — intervention group
Group type: EXPERIMENTAL
Intervention: 35 g xylitol
Number of subjects: 12
Study 33429977 — intervention group
Group type: COMPARATOR
Intervention: tap water (control)
Number of subjects: 12
Study 33378441 — intervention group
Group type: EXPERIMENTAL
Intervention: APC flash‐free brackets
Number of subjects: 30
Study 33378441 — intervention group
Group type: COMPARATOR
Intervention: Conventional ceramic brackets
Number of subjects: 30
Study 34782915 — intervention group
Group type: EXPERIMENTAL
Intervention: Galvanic vestibular stimulation (GVS) coupled with inverse phase rotatory chair impulse in sinusoidal harmonic acceleration protocol
Number of subjects: 30
Study 34782915 — intervention group
Group type: EXPERIMENTAL
Intervention: Galvanic vestibular stimulation (GVS) coupled with inverse phase rotatory chair impulse
Number of subjects: 30
Study 34782915 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 30
Study 33573042 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 PUFA supplementation (142 mg EPA, 267 mg DHA, 12 mg vitamin E, 5 µg vitamin D, six capsules twice a day for three weeks)
Number of subjects: 24
Study 33573042 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 PUFA supplementation
Number of subjects: 24
Study 33573042 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 32574801 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenous Obsessions (AOs)
Number of subjects: 70
Study 32574801 — intervention group
Group type: COMPARATOR
Intervention: Reactive Obsessions (ROs)
Number of subjects: 70
Study 34865513 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendations for conducting and interpreting cardiac surgery trials
Number of subjects: 0
Study 34865513 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial interventions and study end points
Number of subjects: 0
Study 34865513 — intervention group
Group type: EXPERIMENTAL
Intervention: Completeness of follow-up
Number of subjects: 0
Study 34865513 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial design and analytic techniques
Number of subjects: 0
Study 32271672 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg intravenously once every 3 weeks for up to 24 months
Number of subjects: 108
Study 32271672 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 36176007 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation program conducted weekly for 12 weeks in addition to usual care
Number of subjects: 172
Study 36176007 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 172
Study 33758119 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance-exposed newborn vignette with injection heroin use
Number of subjects: 1227
Study 33758119 — intervention group
Group type: COMPARATOR
Intervention: Substance-exposed newborn vignette with prescription opioid use
Number of subjects: 1227
Study 33758119 — intervention group
Group type: COMPARATOR
Intervention: Responses regarding mother's responsibility
Number of subjects: 1227
Study 34687446 — intervention group
Group type: EXPERIMENTAL
Intervention: Fremanezumab (monthly or quarterly)
Number of subjects: 50
Study 35276884 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary fibre supplementation (19.2 g/day) for 2 months
Number of subjects: 0
Study 35276884 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-responders to fibre treatment
Number of subjects: 0
Study 32671515 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy eating intervention
Number of subjects: 299
Study 32671515 — intervention group
Group type: COMPARATOR
Intervention: HPV vaccination (control)
Number of subjects: 299
Study 36040741 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote care (initial in-home visit followed by daily video visit facilitated by the home hospital nurse)
Number of subjects: 172
Study 36040741 — intervention group
Group type: COMPARATOR
Intervention: In-home physician care (control group)
Number of subjects: 172
Study 36040741 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote care
Number of subjects: 172
Study 33257104 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-TT IgG in oral fluid (OF)
Number of subjects: 267
Study 33257104 — intervention group
Group type: EXPERIMENTAL
Intervention: Total IgG in oral fluid specimens
Number of subjects: 267
Study 33257104 — intervention group
Group type: EXPERIMENTAL
Intervention: High oral fluid volume and sucking on the swab
Number of subjects: 267
Study 33257104 — intervention group
Group type: EXPERIMENTAL
Intervention: Total IgG
Number of subjects: 267
Study 33257104 — intervention group
Group type: EXPERIMENTAL
Intervention: Post hoc adjustments for OF volume and total IgG concentration
Number of subjects: 267
Study 33487050 — intervention group
Group type: EXPERIMENTAL
Intervention: Education-based intervention with an educational session and AdhereTech smart bottle with reminder functions activated
Number of subjects: 200
Study 33487050 — intervention group
Group type: COMPARATOR
Intervention: Attention control with a session on general eye health and a smart bottle without reminder functions activated
Number of subjects: 200
Study 33487050 — intervention group
Group type: EXPERIMENTAL
Intervention: Education-based intervention
Number of subjects: 200
Study 35209981 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm infants (various groups based on gestational age)
Number of subjects: 2146
Study 35209981 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm infants (various groups based on birth weight)
Number of subjects: 2146
Study 35209981 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm infants (various groups based on blood collection time)
Number of subjects: 2146
Study 34260175 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4mg
Number of subjects: 132
Study 34260175 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 10mg
Number of subjects: 132
Study 34260175 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study 32135138 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide (10 μg subcutaneous injection three times daily for 26 weeks)
Number of subjects: 108
Study 32135138 — intervention group
Group type: COMPARATOR
Intervention: Placebo (subcutaneous injection three times daily for 26 weeks)
Number of subjects: 108
Study 32135138 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 108
Study 32135138 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 33624377 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline lung cancer stigma (measured by Cataldo Lung Cancer Stigma Scale)
Number of subjects: 194
Study 34592951 — intervention group
Group type: EXPERIMENTAL
Intervention: SMART design
Number of subjects: 100
Study 34592951 — intervention group
Group type: COMPARATOR
Intervention: RCT design
Number of subjects: 100
Study 32042406 — intervention group
Group type: EXPERIMENTAL
Intervention: Food products designed to reduce appetite
Number of subjects: 181
Study 32042406 — intervention group
Group type: COMPARATOR
Intervention: Matching controls
Number of subjects: 181
Study 34873002 — intervention group
Group type: EXPERIMENTAL
Intervention: right@home Nurse Home Visiting (NHV) programme
Number of subjects: 722
Study 34873002 — intervention group
Group type: COMPARATOR
Intervention: usual care (clinic visits)
Number of subjects: 722
Study 33066893 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin plus clopidogrel (dual antiplatelet therapy)
Number of subjects: 1000
Study 33066893 — intervention group
Group type: COMPARATOR
Intervention: Aspirin monotherapy
Number of subjects: 1000
Study 35963028 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg
Number of subjects: 60
Study 35963028 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 33423267 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C19 gene polymorphisms (specifically AG, GG genotypes and A allele of rs4986893 locus)
Number of subjects: 1000
Study 33423267 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP3A5 gene polymorphisms (specifically GG genotype and G allele of rs776746 locus)
Number of subjects: 1000
Study 33423267 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C19 gene polymorphisms (specifically GG genotype of rs4986893 locus)
Number of subjects: 1000
Study 33423267 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP3A5 gene polymorphisms (specifically AA and AG genotypes of rs776746 locus)
Number of subjects: 1000
Study 33423267 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical power of the study
Number of subjects: 1000
Study 34608851 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergonomic welding torch
Number of subjects: 10
Study 34608851 — intervention group
Group type: COMPARATOR
Intervention: Conventional welding torch
Number of subjects: 10
Study 34479613 — intervention group
Group type: EXPERIMENTAL
Intervention: Yijinjing combined with Tuina
Number of subjects: 102
Study 34479613 — intervention group
Group type: COMPARATOR
Intervention: Tuina
Number of subjects: 102
Study 35623152 — intervention group
Group type: EXPERIMENTAL
Intervention: Binaural Beats (BB) intervention starting 5 minutes before and continuing until the end of the colonoscopy procedure.
Number of subjects: 115
Study 35623152 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Binaural Beats), routine nursing care only.
Number of subjects: 115
Study 32712674 — intervention group
Group type: EXPERIMENTAL
Intervention: WISCA utilization for empiric antibiotic prescription
Number of subjects: 6849
Study 32712674 — intervention group
Group type: COMPARATOR
Intervention: Control group (no WISCA utilization)
Number of subjects: 6849
Study 35012783 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 plus bevacizumab 15 mg/kg intravenously every 3 weeks for 3 cycles (bevacizumab arm)
Number of subjects: 82
Study 35012783 — intervention group
Group type: COMPARATOR
Intervention: Concurrent thoracic radiotherapy (TRT) 45 Gy in 25 fractions (TRT arm)
Number of subjects: 82
Study 32142578 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Bone Regeneration (GBR)
Number of subjects: 45
Study 32142578 — intervention group
Group type: COMPARATOR
Intervention: Control (native bone)
Number of subjects: 45
Study 32142578 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 45
Study 33572825 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice germ supplementation (25 g twice a day for 4 weeks)
Number of subjects: 27
Study 33572825 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 32315112 — intervention group
Group type: EXPERIMENTAL
Intervention: mpMRI-targeted biopsy (TBx)
Number of subjects: 150
Study 32315112 — intervention group
Group type: EXPERIMENTAL
Intervention: CUDI-targeted biopsy (TBx)
Number of subjects: 150
Study 32315112 — intervention group
Group type: COMPARATOR
Intervention: Systematic biopsy (SBx)
Number of subjects: 150
Study 35767970 — intervention group
Group type: EXPERIMENTAL
Intervention: Jollab (saffron-based beverage) 20 mL three times daily for 4 weeks
Number of subjects: 75
Study 35767970 — intervention group
Group type: COMPARATOR
Intervention: Placebo 20 mL three times daily for 4 weeks
Number of subjects: 75
Study 33165594 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Spirit Nurture (FSN) intervention
Number of subjects: 134
Study 33165594 — intervention group
Group type: COMPARATOR
Intervention: Injury prevention education control
Number of subjects: 134
Study 32921111 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention and Interpretation Therapy (AIT) for 10 weeks
Number of subjects: 200
Study 32921111 — intervention group
Group type: COMPARATOR
Intervention: Routine intervention measures (Control)
Number of subjects: 200
Study 32239984 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild cleanser and moisturizer used twice daily for two weeks
Number of subjects: 52
Study 32239984 — intervention group
Group type: COMPARATOR
Intervention: Mild cleanser without moisturizer
Number of subjects: 52
Study 34262611 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium picosulfate, magnesium oxide, and citric acid (SPMC) oral solution bowel preparation
Number of subjects: 0
Study 36302983 — intervention group
Group type: EXPERIMENTAL
Intervention: Preservation rhinoplasty (PR)
Number of subjects: 34
Study 36302983 — intervention group
Group type: COMPARATOR
Intervention: Structural rhinoplasty (SR)
Number of subjects: 34
Study 33530186 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved sitting Wuqinxi intervention
Number of subjects: 160
Study 33530186 — intervention group
Group type: COMPARATOR
Intervention: Standardized comprehensive western medicine treatment and routine care
Number of subjects: 160
Study 32621885 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH), median duration 6.2 months (IQR 2.5-12.7)
Number of subjects: 383
Study 32621885 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin, median duration 2.2 years (IQR 0.9-7.1)
Number of subjects: 383
Study 32621885 — intervention group
Group type: COMPARATOR
Intervention: No anticoagulation
Number of subjects: 383
Study 32621885 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary thromboprophylaxis with LMWH
Number of subjects: 383
Study 32621885 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary thromboprophylaxis with warfarin
Number of subjects: 383
Study 32621885 — intervention group
Group type: EXPERIMENTAL
Intervention: LMWH
Number of subjects: 383
Study 32621885 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 383
Study 34256147 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG 2+2L+bisacodyl
Number of subjects: 196
Study 34256147 — intervention group
Group type: COMPARATOR
Intervention: PEG 4+2L+bisacodyl
Number of subjects: 196
Study 33600761 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic nasopharyngectomy (ENPG)
Number of subjects: 200
Study 33600761 — intervention group
Group type: COMPARATOR
Intervention: Intensity-modulated radiotherapy (IMRT)
Number of subjects: 200
Study 33600761 — intervention group
Group type: COMPARATOR
Intervention: IMRT
Number of subjects: 200
Study 33600761 — intervention group
Group type: EXPERIMENTAL
Intervention: ENPG
Number of subjects: 200
Study 33370133 — intervention group
Group type: EXPERIMENTAL
Intervention: OurRelationship (OR) program
Number of subjects: 742
Study 33370133 — intervention group
Group type: EXPERIMENTAL
Intervention: ePREP program
Number of subjects: 742
Study 33370133 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 742
Study 33370133 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative communication improvements
Number of subjects: 742
Study 33370133 — intervention group
Group type: EXPERIMENTAL
Intervention: All mechanisms improvements
Number of subjects: 742
Study 34437308 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed Patient-Centered (IPC) decisions
Number of subjects: 854
Study 34437308 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed Patient-Centered (IPC) decisions for knee patients
Number of subjects: 854
Study 34437308 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed Patient-Centered (IPC) decisions for hip patients
Number of subjects: 854
Study 36411479 — intervention group
Group type: EXPERIMENTAL
Intervention: Esketamine-propofol
Number of subjects: 114
Study 36411479 — intervention group
Group type: COMPARATOR
Intervention: Dexmedetomidine-propofol
Number of subjects: 114
Study 33961115 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief cognitive-behavioral group-intervention (GCBT)
Number of subjects: 313
Study 33961115 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-length cognitive-behavioral group-intervention (GCBT)
Number of subjects: 313
Study 33961115 — intervention group
Group type: COMPARATOR
Intervention: GCBT
Number of subjects: 313
Study 34176196 — intervention group
Group type: EXPERIMENTAL
Intervention: Superficial cryotherapy using DMEP in three freeze–thaw cycles of 5 s each
Number of subjects: 80
Study 34176196 — intervention group
Group type: COMPARATOR
Intervention: Microneedling
Number of subjects: 80
Study 34176196 — intervention group
Group type: EXPERIMENTAL
Intervention: Superficial cryotherapy using DMEP
Number of subjects: 80
Study 34176196 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study 34176196 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 80
Study 32375705 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline-adjusted proportional odds logistic regression models
Number of subjects: 0
Study 32375705 — intervention group
Group type: COMPARATOR
Intervention: Conventional methods (t-tests, Wilcoxon tests)
Number of subjects: 0
Study 35874678 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation (PBM)
Number of subjects: 52
Study 35874678 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 34499109 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenotonsillectomy (AT)
Number of subjects: 393
Study 34499109 — intervention group
Group type: COMPARATOR
Intervention: Watchful waiting
Number of subjects: 393
Study 35152531 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical flutamide plus 5% minoxidil
Number of subjects: 40
Study 35152531 — intervention group
Group type: COMPARATOR
Intervention: Topical 5% minoxidil
Number of subjects: 40
Study 33675203 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Interactive Practice to build Expertise using Real cases (VIPER) with 9 hours of supervised deliberate practice
Number of subjects: 40
Study 33675203 — intervention group
Group type: COMPARATOR
Intervention: Control group (residents)
Number of subjects: 40
Study 34330882 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictorial warnings
Number of subjects: 661
Study 34330882 — intervention group
Group type: COMPARATOR
Intervention: Text-only warnings
Number of subjects: 661
Study 35236353 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention: Physician office reception staff inviting patients to register on a tablet in the waiting room.
Number of subjects: 13562
Study 35236353 — intervention group
Group type: COMPARATOR
Intervention: Control: Usual care without the intervention.
Number of subjects: 13562
Study 32412872 — intervention group
Group type: EXPERIMENTAL
Intervention: Formal attire
Number of subjects: 449
Study 32412872 — intervention group
Group type: EXPERIMENTAL
Intervention: White dress shirt with black pants
Number of subjects: 449
Study 32412872 — intervention group
Group type: EXPERIMENTAL
Intervention: White casual shirt with khaki pants
Number of subjects: 449
Study 32412872 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical scrubs
Number of subjects: 449
Study 32412872 — intervention group
Group type: EXPERIMENTAL
Intervention: White casual shirt with jeans
Number of subjects: 449
Study 32412872 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical scrub top with jeans
Number of subjects: 449
Study 32412872 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical scrub top with khaki pants
Number of subjects: 449
Study 32412872 — intervention group
Group type: EXPERIMENTAL
Intervention: White laboratory coat with khaki pants
Number of subjects: 449